When to Get Tested for Hepatitis C after Exposure
The body begins to release antibodies after the virus particles called HCV RNA are detectable.
CDC National Progress Report on Hepatitis Elimination Reveals Rise in Acute HBV Infections and Low Birth Dose Vaccination Rates in the U.S.
The CDC report reveals continuing challenges in addressing the public health threat of hepatitis B, with new increases in rates of acute hepatitis B infection among adults, particularly those between the ages of 30 and 59 years.
Significance of Day-1 Viral Response of Hepatitis C Virus in Patients with Chronic Hepatitis C Receiving Direct-acting Antiviral Therapy
We evaluated the significance of very early viral response after the start of therapy, which indicates direct HCV response to the drugs, on therapeutic outcome.
Hepatitis C Virus
Sustained Virologic Response
Contrast Enhanced Ultrasound Identifies Hepatocellular Carcinoma in Cirrhosis: A Large Multicenter Retrospective Study
The American College of Radiology has recently released a scheme (CEUS LI-RADS) classifying lesions at risk for HCC investigated by CEUS.
High Risk of Hepatocellular Carcinoma and Death in Patients with Immune-Tolerant-Phase Chronic Hepatitis B
High serum HBV DNA levels are associated with high risks of hepatocellular carcinoma (HCC) and cirrhosis in patients with chronic hepatitis B (CHB).
Upregulation of DARS2 by HBV Promotes Hepatocarcinogenesis Through the miR-30e-5pMAPKNFAT5 Pathway
The osmoregulatory transcription factor nuclear factor of activated T-cells 5 (NFAT5) has been shown to play an important role in the development of many types of human cancers.
Efficacy of NVR 3-778, Alone and in Combination With Pegylated Interferon, vs Entecavir in uPASCID Mice With Humanized Livers and HBV Infection
NVR3-778 has high antiviral activity in mice with humanized livers and stable HBV infection, reducing levels of serum HBV DNA and HBV RNA.
Long-Term Outcome of Hepatitis B Virus-Related Chronic Hepatitis Under Protracted Nucleos(t)ide Analogues
Development of cirrhosis, events of liver decompensation and hepatocellular carcinoma (HCC) during the follow-up were the main endpoints, as the complication-free survival.
Why Do I Treat HBeAg-Positive Chronic Hepatitis B Patients with a Nucleoside Analogue
Sustained suppression of HBV replication is the cornerstone for preventing the progression of disease and prolonging survival in patients with CHB.
Chronic Hepatitis B
Suppression of HBV
Comprehensive Circular RNA Profiling Reveals the Regulatory Role of the CircRNA-100338miR-141-3p Pathway in Hepatitis B-Related Hepatocellular Carcinoma
Circular RNAs (circRNAs) represent a class of endogenous noncoding RNAs that have recently been recognized as important regulators of gene expression and pathological networks.
PRC Online Drug Information Service Certificate No.：(M)-Non-operating-2014-0006
Copyright @ Cosunter Co., Ltd. 2006-2016. All rights reserved
M. ICP. B. No. 11026770 Website statistics